Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
Yayun Liu, Lingling Ge, Shiyong Fan, Aijing Xu, Xinyu Wang, Xu Dong, Mingxiao Xu, Wenhan Fan, Wu Zhong, Xuesong Liang
Infectious Diseases and Therapy, doi:10.1007/s40121-022-00716-7
Introduction: The efficacy of molnupiravir (MLN) on Omicron sublineages is limited. We investigated the effectiveness of MLN in older adults diagnosed with Omicron BA.2. Methods: Data of elderly COVID-19 patients (over 60 years) admitted to Chinghai Hospital (Shanghai, China) from 26 March to 31 May 2022 were reviewed. Study outcomes were a composite of undetectable viral load (VL) and disease progression [all-cause mortality, initiation of oxygen supply through high-flow device or invasive mechanical ventilation (IMV), or intensive care unit (ICU) admission] and their individual outcomes. Results: A total of 42 elderly patients were enrolled: 26 of them received MLN, 17 (40.5%) were males, the median age was 84 years, and 12 were fully vaccinated (31.0%). Among these elderly COVID-19 patients, five (11.90%) experienced obvious dyspnea or were transferred to ICU [three MLN users (11.5%) versus two non-MLN users (12.5%)]. Compared with no MLN use, MLN use was associated with rapid undetectable VL. At day 10, MLN users achieved Yayun Liu, Lingling Ge, and Shiyong Fan are co-first authors.
Author Contributions. Yayun Liu recruited the patients and collected specimens, edited the clinical data and performed the data analysis; Lingling Ge edited the clinical data of enrolled patients; Shiyong Fan drafted the manuscript; Aijing Xu recruited the patients and treated the patients; Wang, Xu Dong, Mingxiao Xu and Wenhan Fan treated the patients; Wu Zhong conceived and designed the study; Xuesong Liang conceived and designed the study; checked the data analysis and drafted the manuscript; All authors have read and approved the final manuscript. Disclosures. Yayun Liu, Lingling Ge, Shiyong Fan, Aijing Xu, Xinyu Wang, XuDong, Mingxiao Xu, Wenhan Fan, Wu Zhong and Xuesong Liang declare that they have no competing interests. Compliance with Ethics Guidelines. This study was approved by the Ethics Committee of Changhai Hospital. (CHEC2022-111).Written informed consent was exempted from all the study participants. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data Availability. All data and analysis results are included in this article. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. All authors have read and approved the final manuscript. Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction..
References
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med,
doi:10.1056/NEJMoa2116044Cao, Li, Yang, The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants, Sci Transl Med,
doi:10.1126/scitranslmed.abm7621Dejnirattisai, Huo, Zhou, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell,
doi:10.1016/j.cell.2021.12.046Guo, Han, Zhang, SARS-CoV-2 omicron variant: epidemiological features, biological characteristics, and clinical significance, Front Immunol,
doi:10.3389/fimmu.2022.877101Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Islam, Dhawan, Nafady, Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: mutational impacts, concerns, and the possible solutions, Ann Med Surg (Lond),
doi:10.1016/j.amsu.2022.103737Mohsin, Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity, Medicine,
doi:10.1097/MD.0000000000029165Smith, Hakim, Leung, COVID-19 mortality and vaccine coverage-Hong Kong Special Administrative Region China, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7115e1Takashita, Kinoshita, Yamayoshi, Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant, N Engl J Med
Vangeel, Chiu, Jonghe, Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern, Antiviral Res,
doi:10.1016/j.antiviral.2022.105252Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study,
doi:10.1101/2022.05.26.22275631Wong, Au, Lau, Lau, Cowling et al., nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA.2 wave: an observational study,
doi:10.1101/2022.05.19.22275291
